Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT05006079

Opioid/Benzodiazepine Polydrug Abuse: Aim 3

Led by Wayne State University · Updated on 2025-12-30

24

Participants Needed

1

Research Sites

141 weeks

Total Duration

On this page

Sponsors

W

Wayne State University

Lead Sponsor

H

Henry Ford Health System

Collaborating Sponsor

AI-Summary

What this Trial Is About

In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphine+alprazolam simultaneously, and placebo (laboratory pharmacology experiment). The latter will enable the investigators to assess the effects of an opioid alone, benzodiazepine alone, concurrent and simultaneous administration of opioid+benzodiazepine, relative to a placebo control.

CONDITIONS

Official Title

Opioid/Benzodiazepine Polydrug Abuse: Aim 3

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Must have self-reported past 10-year use of opioid and sedative drugs or alcohol use on at least 3 separate days in the past month
  • May have mild to moderate Opioid Use Disorder or Sedative Use Disorder
  • Must not be seeking treatment for substance use problems
  • Must be in good overall health
Not Eligible

You will not qualify if you...

  • Current severe psychiatric disorders such as psychosis, bipolar disorder, or severe depression
  • Severe substance use disorder for any substance
  • Past-month prescription of benzodiazepines or opioids
  • Past-year overdose or suicide attempt/ideation
  • Cognitive impairment (IQ less than 80)
  • Neurological, cardiovascular, pulmonary, or systemic diseases
  • Body mass index over 38 kg/m2
  • Females who are pregnant, lactating, or heterosexually active without birth control
  • Treatment with methadone, buprenorphine, or naltrexone
  • Past 30-day use of contraindicated medications
  • Positive breath alcohol sample over 0.02%
  • Positive urine test for methadone, cocaine, amphetamines, or barbiturates
  • Intolerance of lactose

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tolan Park Medical Building

Detroit, Michigan, United States, 48201

Actively Recruiting

Loading map...

Research Team

M

Mark K Greenwald, PhD

CONTACT

H

Heidi Aguas

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here